Literature DB >> 8204577

Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site.

M Shou1, J Grogan, J A Mancewicz, K W Krausz, F J Gonzalez, H V Gelboin, K R Korzekwa.   

Abstract

A unique characteristic of the CYP3A subfamily of cytochrome P450 enzymes is their ability to be activated by certain compounds. It is reported that CYP3A4-catalyzed phenanthrene metabolism is activated by 7,8-benzoflavone and that 7,8-benzoflavone serves as a substrate for CYP3A4. Kinetic analyses of these two substrates show that 7,8-benzoflavone increases the Vmax of phenanthrene metabolism without changing the Km and that phenanthrene decreases the Vmax of 7,8-benzoflavone metabolism without increasing the Km. These results suggest that both substrates (or substrate and activator) are simultaneously present in the active site. Both compounds must have access to the active oxygen, since neither phenanthrene nor 7,8-benzoflavone can competitively inhibit the other substrate. These data provide the first evidence that two different molecules can be simultaneously bound to the same P450 active site. Additionally, structure-activity relationship studies were performed with derivatives of 7,8-benzoflavone structure. The effects of 13 different compounds on the regioselectivity of phenanthrene, chrysene, and benzo[a]pyrene metabolism were determined. Of the 13 compounds studied, 6 were activators, 2 were partial activators, and 5 were inhibitors. Analyses of the data suggest that (1) naphthalene substituted with a ketone in the 2-position can activate 3A4 and (2) the presence of an activator results in a narrower effective substrate binding site. Since the CYP3A enzymes are very important in drug metabolism, the possibility of activation, and autoactivation, must be considered when in vitro-in vivo correlations are made and when possible drug interactions are considered.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8204577     DOI: 10.1021/bi00187a009

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  59 in total

1.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

Authors:  K E Kenworthy; J C Bloomer; S E Clarke; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Allosteric activation of cytochrome P450 3A4 by α-naphthoflavone: branch point regulation revealed by isotope dilution analysis.

Authors:  Caleb M Woods; Cristina Fernandez; Kent L Kunze; William M Atkins
Journal:  Biochemistry       Date:  2011-10-28       Impact factor: 3.162

3.  CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant.

Authors:  Matthew A Hummel; Charles W Locuson; Peter M Gannett; Dan A Rock; Carrie M Mosher; Allan E Rettie; Timothy S Tracy
Journal:  Mol Pharmacol       Date:  2005-06-13       Impact factor: 4.436

Review 4.  The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.

Authors:  Y Zhang; L Z Benet
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules.

Authors:  Daniel R McMasters; Rhonda A Torres; Susan J Crathern; Deborah L Dooney; Robert B Nachbar; Robert P Sheridan; Kenneth R Korzekwa
Journal:  J Med Chem       Date:  2007-06-09       Impact factor: 7.446

Review 6.  Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both?

Authors:  Dmitri R Davydov; James R Halpert
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-12       Impact factor: 4.481

Review 7.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

8.  Exploration of 3,6-dihydroimidazo(4,5-d)pyrrolo(2,3-b)pyridin-2(1H)-one derivatives as JAK inhibitors using various in silico techniques.

Authors:  Radhakrishnan S Jisha; Lilly Aswathy; Vijay H Masand; Jayant M Gajbhiye; Indira G Shibi
Journal:  In Silico Pharmacol       Date:  2017-10-12

9.  Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites.

Authors:  Jin Zhou; Timothy S Tracy; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2009-12-09       Impact factor: 3.922

10.  Effect of glutathione on homo- and heterotropic cooperativity in cytochrome P450 3A4.

Authors:  Dmitri R Davydov; Nadezhda Y Davydova; Tamara N Tsalkova; James R Halpert
Journal:  Arch Biochem Biophys       Date:  2008-01-11       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.